BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27094584)

  • 21. Imatinib-induced eccrine squamous syringometaplasia.
    Van de Voorde K; De Raeve H; Van Regenmortel N; Lambert J
    J Am Acad Dermatol; 2006 Aug; 55(2 Suppl):S58-9. PubMed ID: 16843129
    [No Abstract]   [Full Text] [Related]  

  • 22. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
    Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
    Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the adnexal epithelium: an unusual case of syringometaplasia in a patient on vemurafenib.
    Yu J; Ravikumar S; Plaza JA; Troy JL; Schieke SM
    Am J Dermatopathol; 2015 May; 37(5):e57-60. PubMed ID: 25839889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
    Heakal Y; Kester M; Savage S
    Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.
    El Karak F; Assi T; Kourie HR; El Rassy E; Chebib R; Ghor M; Tabchi S
    Int J Clin Exp Pathol; 2015; 8(3):3294-8. PubMed ID: 26045855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vemurafenib-induced progression of breast cancer: a case report and review of the literature.
    Novik AV; Protsenko SA; Baldueva IA; Ivantsov AO; Nekhaeva TL; Akhaeva ZY; Yanus GA; Iyevleva AG; Imyanitov EN
    Target Oncol; 2016 Apr; 11(2):235-8. PubMed ID: 26264150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vemurafenib-induced DRESS.
    Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
    JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
    [No Abstract]   [Full Text] [Related]  

  • 31. Vemurafenib in melanoma.
    Shaw HM; Nathan PD
    Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-induced eccrine squamous syringometaplasia in an infant.
    Bittar PG; Casady M; Selim MA; Prose NS
    Pediatr Dermatol; 2018 Jan; 35(1):e84-e85. PubMed ID: 29231256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 34. Toxic epidermal necrolysis induced by vemurafenib.
    Lapresta A; Dotor A; González-Herrada C
    Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA approves vemurafenib for treatment of metastatic melanoma.
    Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387
    [No Abstract]   [Full Text] [Related]  

  • 36. Vemurafenib and radiosensitization.
    Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
    JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.
    Cassius C; Pages C; Roux J; Lhote R; Lavocat R; Réa D; Bagot M; Mourah S; Battistella M; Lebbé C; Dumaz N
    J Invest Dermatol; 2016 Jun; 136(6):1302-1305. PubMed ID: 26854489
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
    Myall NJ; Neal JW; Cho-Phan CD; Zhou LY; Stehr H; Zhou L; Diehn M; Wakelee HA
    Clin Lung Cancer; 2016 Mar; 17(2):e17-21. PubMed ID: 26776917
    [No Abstract]   [Full Text] [Related]  

  • 39. Radiosensitization by BRAF inhibitors.
    Strobel SB; Pätzold S; Zimmer L; Jensen A; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2017 Jul; 15(7):703-708. PubMed ID: 28557366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.